Academia Sinica president Wong Chi-huey (翁啟惠) yesterday said Taiwan should set up a research platform to study glycosylation of new drugs produced by local pharmaceutical companies, a move that could help the companies receive drug approvals from the US Food and Drug Administration (FDA).
The Executive Yuan’s Board of Science and Technology (BOST) accepted Wong’s suggestion as one of the conclusions of the three-day Bio Taiwan Committee seminar that ended yesterday. The conclusions will become policy guidelines once approved by the Cabinet.
Wong said companies filing drug applications to the US FDA need to provide information on the glycosylation process of their drugs for review, but most companies do not possess the capability to analyze it.
Therefore, the government should invite the state-funded Development Center for Biotechnology (DCB) and other research institutes to set up a platform to provide the service to local companies, he said.
The understanding of the glycosylation process is crucial to ascertain the effectiveness of biosimilars, which are drugs produced by living organisms, Wong said, adding that biosimiliars are gradually replacing small molecule drugs made up of a chemically based compound to become the main source of new drugs.
The Ministry of Economic Affairs said in the seminar that it has agreed to make biosimiliars the focus of the local pharmaceutical industry, aiming to help local companies launch the first biosimiliar in Taiwan in the near future.
“Since the government cannot spend as much money on biotechnology as China and South Korea, Taiwan should organize our resources more efficiently to compete,” Wong said, citing the South Korean government’s plans to invest US$9 billion in new drug development starting this year to complete the development of 20 new drugs within five years.
However, Wong said he is still optimistic about the local biotechnology industry because about 90 new drugs are undergoing clinical trials.
‘BIG LOSS’: This year might see the last generation of Huawei’s Kirin chips, as their production would stop next month because they are made using US technology Chinese tech giant Huawei Technologies Co (華為) is running out of processor chips to make smartphones due to US sanctions and would be forced to stop production of its own most advanced chips, a company executive has said, in a sign of growing damage to Huawei’s business from US pressure. Huawei, one of the biggest producers of smartphones and network equipment, is at the center of US-Chinese tension over technology and security. Washington last year cut off Huawei’s access to US components and technology, and those penalties were tightened in May, when the White House barred vendors worldwide from using US
’WHITE BOX’: The open platform would give local firms access to Cisco’s cloud-based mobile network to develop 5G telecom equipment and tap into the global market The Ministry of Economic Affairs (MOEA) yesterday introduced a new 5G “open lab” in collaboration with US-based information technology and networking giant Cisco Systems Inc to address the rapidly growing “white box” 5G networking equipment market. The open lab will be a platform where Taiwanese manufacturers can access Cisco’s cloud-based mobile network to develop their own 5G telecom equipment, such as small-cell base stations, network switches, modems and Internet of things (IoT) devices, a ministry statement said. The open platform would allow Taiwanese manufacturers to tap into the lucrative 5G telecom equipment market, which was previously monopolized by Nokia Oyj, Ericsson AB
CORPORATE SCANDAL: Cathay Life has invested NT$13.3 billion in Bank Mayapada since 2015, but the latest loss of NT$8.8 billion has completely written off its investment Cathay Life Insurance Co (國泰人壽) yesterday said it would recognize an investment loss of NT$8.8 billion (US$298.1 million) in Indonesia’s Bank Mayapada Internasional Tbk PT due to concerns about the lender’s operations amid a corporate scandal. The company said it would revise its earnings result for June, from a net profit of NT$6.52 billion to a net loss of NT$520 million, its first monthly loss over the past 17 months. After booking an investment loss of NT$5.2 billion in Bank Mayapada earlier this year, Cathay Life has so far recognized total investment losses of NT$14 billion in the lender, executive vice president
Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) yesterday reported that revenue last month expanded 25 percent annually, but fell 12.8 percent month-on-month to NT$105.96 billion (US$3.59 billion). In the first seven months of this year, the chipmaker’s revenue surged 33.6 percent to NT$727.26 billion, compared with NT$544.46 billion a year earlier. TSMC has said it aims to grow its revenue by more than 20 percent this year. The company has since May 15 stopped taking new orders from Huawei Technologies Co (華為), its second-biggest customer after Apple Inc, due to the US’ restrictions on exports containing US technologies. TSMC has no plans to